Literature DB >> 17149544

Effects of timed administration of doxycycline or methylprednisolone on post-myocardial infarction inflammation and left ventricular remodeling in the rat heart.

Ricardo A Garcia1, Katrina V Go, Francisco J Villarreal.   

Abstract

The development of strategies to ameliorate post-myocardial infarction (MI) remodeling and improve function continues to be an area of clinical importance. Use of steroids for this purpose is controversial since the effects of timed treatment on relevant inflammatory, biochemical and structure/function endpoints are unclear. In a previous report, we demonstrated that use of doxycycline pre-treatment improves post-MI remodeling and passive left ventricular (LV) function. However, the effects of timed doxycycline post-MI treatment are unknown. To examine these issues, we performed a study using a rat MI model. Animals were administered one of the following: doxycycline (DOX), the corticosteroid methylprednisolone (MP), or aqueous vehicle. Treatment was given early, short-term (at time of MI to 24 h post-MI) or late, long term (2-7 days post-MI). Animals were sacrificed at 3, 7 or 42 days post-surgery. We assessed LV hemodynamics, pressure-volume, and pressure-scar strains, histomorphometry, inflammation via measurements of myeloperoxidase activity, and matrix metalloproteinase (MMP) activity. Late MP treatment yielded a robust right-shifted pressure-volume curve, which was accompanied by increased scar strains. Late DOX treatment yielded reduced average heart weight and size and preserved scar thickness. DOX treatment did not suppress inflammation, which contrasts with the suppressive effects of MP. Use of early or late MP yielded increased MMP activity in infarcted and non-infarcted regions. Early and late treatment with DOX yielded infarct-associated MMP activity levels comparable to those of vehicle-treated animals. In conclusion, results indicate that late use of MP yields adverse post-MI structure/function outcomes that correlate with suppression of inflammation and increased MMP activity. These observations contrast with those of DOX, in particular, late treatment where improved outcomes were observed in LV structure and were accompanied by the lack of suppression of inflammation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17149544     DOI: 10.1007/s11010-006-9379-0

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.842


  44 in total

Review 1.  Tetracyclines: nonantibiotic properties and their clinical implications.

Authors:  Allen N Sapadin; Raul Fleischmajer
Journal:  J Am Acad Dermatol       Date:  2006-02       Impact factor: 11.527

2.  The long-term effects of a single dose of methyl prednisolone on 35S uptake in ocular and nasal tissue.

Authors:  R T Jackson; M B Waitzman
Journal:  Biochem Pharmacol       Date:  1967-06       Impact factor: 5.858

3.  Protective action of methylprednisolone on the myocardium during experimental myocardial ischemia in the cat.

Authors:  J A Spath; D L Lane; A M Lefer
Journal:  Circ Res       Date:  1974-07       Impact factor: 17.367

Review 4.  The inflammatory response in myocardial infarction.

Authors:  Nikolaos G Frangogiannis; C Wayne Smith; Mark L Entman
Journal:  Cardiovasc Res       Date:  2002-01       Impact factor: 10.787

Review 5.  Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications.

Authors:  M A Pfeffer; E Braunwald
Journal:  Circulation       Date:  1990-04       Impact factor: 29.690

Review 6.  Methylprednisolone interventions in myocardial infarction: a controversial subject.

Authors:  Y M LeGal; L L Morrissey
Journal:  Can J Cardiol       Date:  1990-11       Impact factor: 5.223

7.  Abnormal cardiac wall motion and early matrix metalloproteinase activity.

Authors:  Ricardo A García; Kristian L Brown; Richard S Pavelec; Katrina V Go; James W Covell; Francisco J Villarreal
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-10-14       Impact factor: 4.733

8.  Early degradation and serum appearance of type I collagen fragments after myocardial infarction.

Authors:  Francisco Villarreal; Jeffrey Omens; Wolfgang Dillmann; Juha Risteli; Judy Nguyen; James Covell
Journal:  J Mol Cell Cardiol       Date:  2004-04       Impact factor: 5.000

9.  Accumulation of 99mTc-tetracycline in lung infarction area. An experimental study.

Authors:  J Lichey; G Charissis; M Braunsdorf; J Franke; W Hahn
Journal:  Respiration       Date:  1979       Impact factor: 3.580

10.  Early short-term treatment with doxycycline modulates postinfarction left ventricular remodeling.

Authors:  Francisco J Villarreal; Michael Griffin; Jeffrey Omens; Wolfgang Dillmann; Judy Nguyen; James Covell
Journal:  Circulation       Date:  2003-09-02       Impact factor: 29.690

View more
  15 in total

Review 1.  Myocardial matrix metalloproteinase-2: inside out and upside down.

Authors:  Ashley DeCoux; Merry L Lindsey; Francisco Villarreal; Ricardo A Garcia; Richard Schulz
Journal:  J Mol Cell Cardiol       Date:  2014-09-28       Impact factor: 5.000

Review 2.  Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature.

Authors:  Michael O Griffin; Eduardo Fricovsky; Guillermo Ceballos; Francisco Villarreal
Journal:  Am J Physiol Cell Physiol       Date:  2010-06-30       Impact factor: 4.249

3.  Platelet-derived growth factor blockade on cardiac remodeling following infarction.

Authors:  Chang Liu; Wenyuan Zhao; Weixin Meng; Tieqiang Zhao; Yuanjian Chen; Robert A Ahokas; Hongyu Liu; Yao Sun
Journal:  Mol Cell Biochem       Date:  2014-08-23       Impact factor: 3.396

4.  Effects of (-)-epicatechin on myocardial infarct size and left ventricular remodeling after permanent coronary occlusion.

Authors:  Katrina Go Yamazaki; Pam R Taub; Maraliz Barraza-Hidalgo; Maria M Rivas; Alexander C Zambon; Guillermo Ceballos; Francisco J Villarreal
Journal:  J Am Coll Cardiol       Date:  2010-06-22       Impact factor: 24.094

Review 5.  Targeting matrix metalloproteinases in heart disease: lessons from endogenous inhibitors.

Authors:  Francis G Spinale; Francisco Villarreal
Journal:  Biochem Pharmacol       Date:  2014-04-26       Impact factor: 5.858

6.  Doxycycline attenuates protein aggregation in cardiomyocytes and improves survival of a mouse model of cardiac proteinopathy.

Authors:  Hanqiao Zheng; Mingxin Tang; Qingwen Zheng; Asangi R K Kumarapeli; Kathleen M Horak; Zongwen Tian; Xuejun Wang
Journal:  J Am Coll Cardiol       Date:  2010-10-19       Impact factor: 24.094

7.  Short- and long-term effects of (-)-epicatechin on myocardial ischemia-reperfusion injury.

Authors:  Katrina Go Yamazaki; Diego Romero-Perez; Maraliz Barraza-Hidalgo; Michelle Cruz; Maria Rivas; Brenda Cortez-Gomez; Guillermo Ceballos; Francisco Villarreal
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-06-20       Impact factor: 4.733

8.  Modulating In Vivo Degradation Rate of Injectable Extracellular Matrix Hydrogels.

Authors:  Jean W Wassenaar; Rebecca L Braden; Kent G Osborn; Karen L Christman
Journal:  J Mater Chem B       Date:  2016-03-28       Impact factor: 6.331

9.  Computational model predicts paracrine and intracellular drivers of fibroblast phenotype after myocardial infarction.

Authors:  Angela C Zeigler; Anders R Nelson; Anirudha S Chandrabhatla; Olga Brazhkina; Jeffrey W Holmes; Jeffrey J Saucerman
Journal:  Matrix Biol       Date:  2020-03-21       Impact factor: 11.583

10.  A role for non-antimicrobial actions of tetracyclines in combating oxidative stress in periodontal and metabolic diseases: a literature review.

Authors:  M Soory
Journal:  Open Dent J       Date:  2008-01-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.